论文部分内容阅读
[目的]探讨CD147和MMP9在乳腺浸润性导管癌中的表达及意义。[方法]应用免疫组织化学方法SP法检测60例乳腺浸润性导管癌及60例乳腺纤维腺瘤组织中CD147和MMP9的表达情况。[结果]CD147及MMP9在60例乳腺纤维腺瘤中均阴性表达,CD147、MMP9在乳腺浸润性导管癌中的阳性表达率分别为91.7%(55/60)和86.7%(52/60)(P均=0.000)。CD147和MMP9的表达均与乳腺浸润性导管癌患者的组织学分级及淋巴结转移相关,与年龄、肿瘤大小、家族史及临床分期无关。CD147和MMP9在乳腺浸润性导管癌中表达呈显著性相关(r=0.830)。[结论]CD147和MMP9在乳腺浸润性导管癌中高表达,两者在乳腺癌的发生发展中发挥着重要作用。
[Objective] To investigate the expression and significance of CD147 and MMP9 in breast invasive ductal carcinoma. [Method] Immunohistochemical SP method was used to detect the expression of CD147 and MMP9 in 60 cases of breast invasive ductal carcinoma and 60 cases of breast fibroadenoma. [Results] The positive expression rates of CD147 and MMP9 in 60 cases of breast fibroadenoma were 91.7% (55/60) and 86.7% (52/60), respectively P = 0.000). The expressions of CD147 and MMP9 were correlated with the histological grade and lymph node metastasis in patients with invasive ductal carcinoma, but not with age, tumor size, family history and clinical stage. The expression of CD147 and MMP9 in invasive ductal carcinoma of the breast was significantly correlated (r = 0.830). [Conclusion] CD147 and MMP9 are highly expressed in invasive ductal carcinoma of the breast, both of which play an important role in the development of breast cancer.